The in-video title of this recording is currently incorrect. We apologise for any inconvenience.

Building upon the discussion of a damage repair paradigm from days 1 and 2, this panel weighed the benefits of application of a damage repair paradigm to drug development to combat the diseases of aging. Discussion included the feasibility of applying such a strategy, the advantages and disadvantages such a model would confer, and an analysis of the regulatory changes that would be required to make such a paradigm possible.

Participants:

• Richard Barker, Director, Center for the Advancement of Sustainable Medical Innovation (Moderator)
• Julie Allickson, Director, Translational Research, Wake Forest Institute for Regenerative Medicine
• Stephen Minger, Chief Scientist, Cellular Sciences, GE Healthcare Life Sciences, UK
• Evan Snyder, Director, Center for Stem Cell and Regenerative Medicine, Director, Stem Cell Research Center and Core Facility, Sanford-Burnham Medical Research Institute